For the latest COVID information Click Here.
Approval is required to advertise surveys to the ARA Membership. The procedure for Surveys of the Membership can be found here. Please advise:
Please enclose a copy of the survey, the research protocol and ethics approval with your application and send to ara@rheumatology.org.au.
Click here to complete the survey.
Researchers at The George Institute & UNSW are conducting a survey to explore key barriers and facilitators to translating research findings into practice, more specifically musculoskeletal surgery. By participating in this survey, you will help identify the key barriers and facilitators to implementing research results in surgery, with the goal of improving patient outcomes.
You have been invited because of your expertise in clinical or research fields related to musculoskeletal surgery. Your insights are invaluable in helping us understand the factors that influence the adoption of evidence in clinical practice.
The research project is looking for people who want to take part in this research and who are: i. Age > 18 years ii. And either 1. Healthcare professional currently practicing in Australia and who has cared for patients with musculoskeletal conditions in the past 12 months OR 2. Clinical researcher who has worked in the field of musculoskeletal health for at least 12 months
Participation in this research is not a requirement and your decision to or not to take part is optional and voluntary.
It will take approximately 10 minutes to complete the survey outlined in the attached Participant Information Statement, which contains a full description of the research activities, risks associated with these activities and any discomforts that you may experience during the research. If you would like to take part in this research, you can do so by selecting the following link: https://redcap.link/TGIMSKSURVEY
Survey Closes: 16 February 2025
Date Posted: 2 December 2024
Do you have patients on or ≥2 advanced immunosuppressive therapies (eg biological agents) concurrently that are not typically used in combination?
Researchers from the University of Sydney are looking to assess the important and emerging area of outcomes of these patients, via an online de-identified registry. All data is stored securely and in the strictest of confidence, and the study has been granted Human Research Ethics Committee approval.
Please follow this link for the database to fill out patient details or receive further details. The survey takes 5-10 minutes (per patient). Any clinician who fills ≥10 patients will be offered co-authorship on the academic output.
Many thanks in advance for your time
Dr John Chetwood (john.chetwood@health.nsw.gov.au) On behalf of the The Multiple Advanced Therapies Research Team
Survey Closes: 1 March 2025
Date Posted: 4 January 2024
The purpose of this 5-minute survey is to establish an understanding of the knowledge and attitudes about cannabis by rheumatologists and those who care for people with rheumatic diseases from around the world. The survey will likely close April 30, 2024. Please contact Dr. Kaleb Michaud at rheumkap@ndb.org or call +1-316-263-2125 for more information or questions.
If you have questions about your rights as a research subject, you may contact Solutions IRB at +1-855-226-4472 or participants@solutionsirb.com.
Click here to read the privacy statement.
Survey Closes: 31 December 2024
Date Posted: 28 February 2024
Endocrinologists Prof Rory Clifton-Bligh and Dr Shejil Kumar are requesting your assistance with estimating the prevalence of X-linked hypophosphataemia (XLH) amongst adults in Australia and to characterise the Australian adult XLH cohort.
If you have managed any adult patients with XLH in the past ten years, then we invite you to complete this survey. The survey will ask questions about the patients' clinical course, complications and treatment. The survey takes approximately 15 minutes to complete per patient and your progress can be saved and returned to at a later time if needed. We acknowledge that completing this survey requires your time and we would really appreciate your contribution to this research.
The study has been approved by the local ethics committee (NSLHD) and results are securely stored on a REDCap database.
If you have any questions about the study, please feel free to contact Dr Shejil Kumar at shejil.kumar@health.nsw.gov.au.
Survey Closes: 14 February 2025
Date Posted: 9 October 2024
Bisphosphonates are the recommended initial therapy for the management of osteoporosis. Some clinicians may be wary of prescribing IV bisphosphonates due to concerns patients may experience an acute phase response (APR). There are no clear guidelines regarding how to avoid or reduce this potential APR. Several medications have been trialled to treat the APR associated with intravenous zoledronate infusion. The aim of this survey is to identify common prescribing practices with regards to supplementary treatment to reduce APR following zoledronate infusion which will allow adjustments to existing prescribing protocols with the objective of reducing APR risk.
This survey has been approved as a Quality Assurance activity by Liverpool Hospital Clinical Goverance Unit (Reference Number: LIV261/2024/59).
If you have any questions about the study, please feel free to contact Dr Stephen Sweeney at Stephen.sweeney@health.nsw.gov.au
Thank you for your consideration in participating in this study.
Survey Closes: 6 January 2025
Date Posted: 22 November 2024